Endocrine Disorders: Evaluation and Management
Summary
- Gliflozins (also known as SGLT2 inhibitors) block reabsorption of glucose[Riser Taylor 2013]
- The FDA has approved 3 drugs in this class: canagliflozin, dapagliflozin, and empagliflozin[FDA Canagliflozin; FDA Dapagliflozin; FDA Empagliflozin]
- Benefits of canagliflozin, dapagliflozin, and empagliflozin include weight loss, lower blood pressure, and lack of hypoglycemia[FDA Canagliflozin; FDA Dapagliflozin; FDA Empagliflozin]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Diabetes, Endocrine Disorders